{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:09:14Z","timestamp":1788728954095,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmorw.2025.100665","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:28:26Z","timestamp":1767716906000},"page":"100665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Second-line therapies after CDK4\/6 inhibitor failure in HR-positive\/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-6935","authenticated-orcid":false,"given":"M.E.","family":"Cazzaniga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cogliati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-7618","authenticated-orcid":false,"given":"E.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Borella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5410","authenticated-orcid":false,"given":"O.","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-6769","authenticated-orcid":false,"given":"A.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Madaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Coltelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.L.","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zustovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Landucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gamucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.F.","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Capici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.esmorw.2025.100665_bib1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100665_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100665_bib3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100665_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100665_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.esmorw.2025.100665_bib6","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100665_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.esmorw.2025.100665_bib8","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100665_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100665_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","article-title":"Systemic therapies following progression on first-line CDK4\/6-inhibitor treatment: analysis of real-world data","volume":"27","author":"Martin","year":"2022","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100665_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/oncolo\/oyad035","article-title":"Real-world evaluation of disease progression after CDK 4\/6 inhibitor therapy in patients with hormone receptor-positive metastatic breast cancer","volume":"28","author":"West","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.esmorw.2025.100665_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115113","article-title":"The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study","volume":"213","author":"Molinelli","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100665_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61067","article-title":"Survival following CDK4\/6 inhibitor therapy for hormone receptor-positive, ERBB2-negative metastatic breast cancer","volume":"8","author":"Berton Giachetti","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100665_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/s12885-024-12269-8","article-title":"Systematic literature review of real-world evidence for treatments in HR+\/HER2- second-line LABC\/mBC after first-line treatment with CDK4\/6i","volume":"24","author":"Lambert","year":"2024","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100665_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/OP-24-00649","article-title":"Efficacy of subsequent treatments after disease progression on CDK4\/6 inhibitors in patients with hormone receptor-positive advanced breast cancer","volume":"21","author":"Ravani","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmorw.2025.100665_bib16","article-title":"Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4\/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective\/prospective observational trial GOIRC-04-2019","volume":"8","author":"Moscetti","year":"2025","journal-title":"ESMO Real World Data Digital Oncol"},{"issue":"17","key":"10.1016\/j.esmorw.2025.100665_bib17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmorw.2025.100665_bib18","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100665_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.188315","article-title":"The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials","volume":"1872","author":"Najim","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100665_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmorw.2025.100665_bib21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:18:01Z","timestamp":1788725881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125005545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S2949820125005545"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100665","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line therapies after CDK4\/6 inhibitor failure in HR-positive\/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100665"}}